Asima Hussaini, MD
Internal Medicine · Bourbonnais, ILNPI 1437110970
Payments from drug & device makers
Across 351 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$704
- Novo Nordisk$696
- AbbVie$688
- Lilly USA, LLC$454
- Boehringer Ingelheim$444
- AstraZeneca$416
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,153100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 40 | $704 |
| Novo Nordisk | 45 | $696 |
| AbbVie(2 entities) | 46 | $688 |
| Lilly USA, LLC | 26 | $454 |
| Boehringer Ingelheim | 23 | $444 |
| AstraZeneca | 20 | $416 |
| Amgen | 31 | $415 |
| Organogenesis Inc. | 14 | $409 |
| Pfizer | 18 | $302 |
| Johnson & Johnson | 11 | $278 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $189 |
| Merck | 8 | $130 |
| Abbott | 5 | $98 |
| Bayer | 6 | $88 |
| Acera Surgical, Inc. | 1 | $77 |
| Exact Sciences | 3 | $52 |
| KCI USA, Inc. | 4 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $47 |
| Dexcom, Inc. | 2 | $46 |
| Mylan Specialty L.p. | 3 | $45 |
| Misonix Inc | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Smith+Nephew | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Phadia US Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Novartis | 2 | $27 |
| Electromed, Inc. | 1 | $24 |
| Verona Pharma, Inc. | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Urgo Medical North America, LLC | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $17 |
| Impel Pharmaceuticals Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Apligraf$102
How this compares
$6,153 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 64 | $73,177 |
| JardianceEmpagliflozin | 39 | $59,730 |
| OzempicSemaglutide | 35 | $55,039 |
| FarxigaDapagliflozin Propanediol | 39 | $52,142 |
| EliquisApixaban | 26 | $35,124 |
| JanuviaSitagliptin Phosphate | 29 | $26,114 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $21,155 |
| XareltoRivaroxaban | 12 | $19,155 |
| TradjentaLinagliptin | 12 | $16,106 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $14,024 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $6,733 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $5,701 |
| Duloxetine Hcl | 69 | $5,512 |
| Atorvastatin Calcium | 355 | $2,989 |
| Levothyroxine Sodium | 347 | $2,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $444 | $75,83651 claims |
| Lilly USA, LLCMounjaro | $454 | $73,17764 claims |
| AstraZenecaFarxiga, Symbicort | $416 | $58,87553 claims |
| Novo NordiskOzempic | $696 | $55,03935 claims |
| PfizerEliquis | $302 | $35,12426 claims |
| MerckJanuvia | $130 | $26,11429 claims |
| Johnson & JohnsonXarelto | $278 | $19,15512 claims |
| GSKBreo Ellipta | $704 | $14,02428 claims |
| AbbVieSynthroid | $688 | $2,15929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Bourbonnais
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.